GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 35 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $93,459,609 | +248.6% | 9,308,726 | 0.0% | 1.87% | +227.9% |
Q3 2023 | $26,809,131 | -22.1% | 9,308,726 | +3.0% | 0.57% | -8.8% |
Q2 2023 | $34,418,496 | +94.8% | 9,033,726 | -4.9% | 0.62% | +79.8% |
Q1 2023 | $17,665,860 | -2.6% | 9,497,774 | +20.5% | 0.35% | 0.0% |
Q4 2022 | $18,135,201 | -28.6% | 7,884,870 | 0.0% | 0.35% | -26.3% |
Q3 2022 | $25,389,000 | -41.5% | 7,884,870 | 0.0% | 0.47% | -40.1% |
Q2 2022 | $43,367,000 | +136.0% | 7,884,870 | 0.0% | 0.79% | +163.8% |
Q1 2022 | $18,372,000 | -61.4% | 7,884,870 | 0.0% | 0.30% | -51.3% |
Q4 2021 | $47,625,000 | -56.5% | 7,884,870 | 0.0% | 0.61% | -49.1% |
Q3 2021 | $109,363,000 | +6.7% | 7,884,870 | 0.0% | 1.20% | +15.9% |
Q2 2021 | $102,503,000 | -15.6% | 7,884,870 | 0.0% | 1.04% | -8.6% |
Q1 2021 | $121,427,000 | – | 7,884,870 | – | 1.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
Capital International Sarl | 228,149 | $532,000 | 0.03% |
FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |